Book an Appointment
Mr Parijat Bhattacharjee, Private Consultant Gynaecologist, Harrow, Brentford, Northwood, London, UK / Media / Videos » CA 125 Cancer Antigen 125

CA 125 Cancer Antigen 125

CA 125 Cancer Antigen 125
Posted on: 03-Jul-2026

This video, titled "CA 125 Cancer Antigen 125" by Gynae Consultant, provides a comprehensive look at the CA-125 blood test. It explains the historical context of its discovery, its baseline limits, the wide range of conditions that cause it to fluctuate, and its limitations as a diagnostic tool.

Discovery and Meaning

  • The Name: "CA" stands for Cancer Antigen. It was discovered in the 1970s during research into immunotherapy treatments for ovarian cancer.
  • The Number: The "125" signifies that it was found after successive, multiple experimental attempts (symbolically the 125th attempt) to find a specific marker that antibodies could target on ovarian cancer cells.

Lack of Specificity

Despite its origins, CA-125 is not exclusively specific to ovarian cancer. It is naturally produced by epithelial cells lining the normal female reproductive tract (uterus, fallopian tubes), the abdominal cavity (peritoneum), and even the linings of the lungs (pleura) and heart (pericardium). Because of this, its levels can rise due to general irritation or inflammation in any of these areas.

Normal Limits and Baseline Numbers

  • The Baseline: The upper limit of a normal result is widely quoted as 35 international units (IU).
  • Correlation: Early research found that roughly 82% of women with advanced ovarian cancers (Stages 2, 3, and 4) presented with a CA-125 level above 35. In contrast, only about 1 in 888 women in the general healthy population will exhibit a randomly elevated result.

Common Causes of Elevated CA-125

Because it reacts to inflammation and tissue changes, elevated levels are frequently tied to completely benign conditions, as well as non-ovarian malignancies:

Benign Gynecological Conditions

  • Menstruation: Levels can naturally double or triple during a normal period, or rise during the first 14 days (proliferative phase) of the cycle.
  • Pregnancy
  • Endometriosis
  • Uterine Fibroids
  • Acute Pelvic Infections (PID)
  • Benign Ovarian Tumors (such as those associated with Meigs' syndrome)

Non-Gynecological Conditions

  • Gastrointestinal Issues: Diverticulosis, appendicitis, and pancreatitis.
  • Organ Stress: Various liver conditions and heart failure.

Other Malignancies

  • Pancreatic cancer and breast cancer that has metastasized to the abdomen.

Diagnostic Value and Clinical Limitations

  • The Early Stage Problem: The test has low sensitivity for early-stage disease. Around 50% of women with Stage 1 ovarian cancer will still return a perfectly normal CA-125 result.
  • Not an Ideal Screening Tool: Because it is neither highly sensitive for early stages nor strictly specific to ovarian tissue, it is not recommended for routine, widespread cancer screening. Exceptions are made for high-risk individuals, such as those with a strong family history or BRCA gene mutations.
  • Premenopausal vs. Postmenopausal Women: The test is significantly more reliable and specific in postmenopausal women. This is because normal confounding factors like menstruation, pregnancy, fibroids, and endometriosis are no longer present. In a postmenopausal woman, a highly elevated result (particularly over 200 IU) is much more indicative of potential pathology.
  • Specific Tumor Types: The test only reliably detects certain types of epithelial ovarian cancers. Other variants, such as mucinous or clear cell ovarian cancers, often do not trigger a rise in CA-125 levels.
  • Treatment and Recurrence Monitoring: Where CA-125 excels is in monitoring known cases. Doctors use it to evaluate how well a patient is responding to ongoing cancer therapy and to track potential early recurrences post-treatment.